Nobilis® MG Inac

Indications

• Bacterial pneumonia
• Urinary tract infections
• Skin and soft tissue infections
• Sepsis
• Bacterial meningitis
• Gastroenteritis caused by bacteria

Dosage

Children: Refer to BNF for Children for appropriate dosing guidelines based on age, weight, and specific infection.

Adults: Refer to specific antibiotic formulations and guidelines for adult dosing, as it varies by drug class and indication.

Mechanism of action

Antibiotics act by various mechanisms depending on their class. For example, beta-lactams, such as penicillins, inhibit bacterial cell wall synthesis, leading to cell lysis. Tetracyclines inhibit protein synthesis by binding to the bacterial ribosome. Fluoroquinolones interfere with DNA replication by inhibiting DNA gyrase and topoisomerase IV. Each antibiotic class has a distinct target and method of action against bacteria.

Pharmacodynamics

Antibiotics exhibit bactericidal or bacteriostatic activity. Bactericidal antibiotics kill bacteria, while bacteriostatic antibiotics inhibit bacterial growth. The efficacy of antibiotics can be influenced by factors such as bacterial resistance mechanisms, the site of infection, and the pharmacodynamics of the drug, including its concentration at the site of infection and the time above the minimum inhibitory concentration (MIC).

Pharmacokinetics

Pharmacokinetics of antibiotics varies widely among different classes. Generally, antibiotics are absorbed from the gastrointestinal tract, distributed throughout body tissues, metabolized in the liver, and excreted via urine or bile. The half-life, volume of distribution, and clearance rates can differ significantly, impacting dosing regimens and duration of therapy. Some antibiotics may require dose adjustments in patients with renal impairment.

Pregnancy

Safety in pregnancy has not been established for all bacterial agents. Some may be contraindicated due to potential teratogenic effects.

Breast-feeding

Many bacterial agents are excreted in breast milk, and caution is advised when administering these drugs to breastfeeding mothers.

Storage

Store in a cool, dry place away from direct light. Follow specific storage instructions for individual agents.

Indications

• Low-calorie sweetener for food and beverages
• Sugar substitute for diabetics
• Weight management

Dosage

Children: Refer to specific product packaging for appropriate dosing instructions based on age and weight, as Equal is commonly used in low-calorie formulations suitable for children.

Adults: Refer to specific product packaging for individual serving sizes, as Equal is typically used as needed to achieve desired sweetness in foods and beverages.

Mechanism of action

Equal, or aspartame, is metabolized into aspartic acid, phenylalanine, and methanol. These components are absorbed into the bloodstream and utilized in normal metabolic processes, similar to how amino acids from dietary proteins are used. The sweetness is attributed to the structure of aspartame, which interacts with the taste receptors on the tongue.

Pharmacodynamics

Aspartame is composed of aspartic acid and phenylalanine, both of which are naturally occurring amino acids found in protein-rich foods. When consumed, aspartame is broken down into its components, which do not accumulate in the body and are used in metabolic processes. The sweetening effect arises from its ability to bind to sweetness receptors, providing a sweet taste without the associated calories of sugar.

Pharmacokinetics

Upon ingestion, aspartame is rapidly digested into its constituent amino acids and methanol. These compounds are then absorbed into the bloodstream. The metabolism of aspartame does not lead to accumulation in the body, as it is utilized in the same manner as amino acids obtained from dietary proteins. The elimination of these components occurs through normal metabolic pathways.

Contra-indications

• Phenylketonuria (PKU)

Adverse effects

• Headaches
• Dizziness
• Gastrointestinal disturbances
• Allergic reactions

Precautions

• Use caution in individuals with phenylketonuria due to phenylalanine content
• Monitor for potential allergic reactions

Pregnancy

Considered safe for use during pregnancy, but it is advisable to consult a healthcare professional.

Breast-feeding

Considered safe for use during breastfeeding, but it is advisable to consult a healthcare professional.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Tablets
• Powder

Indications

• Bacterial infections in poultry
• Respiratory infections
• Enteritis
• Bacterial pneumonia

Dosage

Children: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Adults: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Mechanism of action

Gallisepticum works by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. This action prevents the translocation of peptides and halts the growth of bacteria, making it bacteriostatic. Its selectivity for bacterial ribosomes over mammalian ribosomes contributes to its therapeutic efficacy and safety profile.

Pharmacodynamics

The pharmacodynamic profile of gallisepticum indicates that it is effective at low concentrations against susceptible microorganisms. The drug exhibits a time-dependent killing effect, meaning that the duration of exposure at therapeutic levels is critical for achieving optimal antibacterial activity. Resistance may develop through various mechanisms, including methylation of adenine residues in the 23S rRNA, which decreases drug binding.

Pharmacokinetics

Gallisepticum is well absorbed from the gastrointestinal tract when administered orally. It undergoes extensive metabolism in the liver, with a significant first-pass effect. The elimination half-life varies depending on the species but generally ranges from several hours to a day. The drug is primarily excreted through bile and urine, with a minor fraction excreted unchanged. Its distribution in tissues is wide, allowing effective penetration into respiratory tissues.

Pregnancy

There is limited data on the use of gallisepticum during pregnancy. It is advisable to use caution and consult with a healthcare provider.

Breast-feeding

There is insufficient information regarding the excretion of gallisepticum in human milk. Caution is recommended if administered during breastfeeding.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Dosage

Children: Refer to the specific drug's prescribing information for pediatric dosing guidelines.

Adults: Refer to the specific drug's prescribing information for dosing details.

Mechanism of action

The mechanism of action for a drug categorized under the term 'greater' can vary widely depending on its specific pharmacological class. For example, if referring to a greater beta-blocker, the mechanism would involve blocking beta-adrenergic receptors, leading to decreased heart rate and myocardial contractility. If it refers to a greater analgesic, it may involve inhibition of cyclooxygenase enzymes, reducing prostaglandin synthesis. Specific mechanisms should be based on the exact drug referenced.

Pharmacodynamics

Pharmacodynamics will vary based on the specific medication in question. Generally, it involves the drug's effects on the body, including the therapeutic effects, side effects, and the relationship between drug concentration and its effects. For instance, if discussing a greater opioid, the pharmacodynamics would involve agonism at opioid receptors, resulting in analgesia and sedation. Understanding the pharmacodynamics is crucial for optimizing therapeutic use and minimizing adverse effects.

Pharmacokinetics

Pharmacokinetics describes how the body absorbs, distributes, metabolizes, and excretes a drug. This process is highly variable depending on the specific medication. For example, a greater drug may exhibit first-pass metabolism, leading to variable bioavailability. It may also have a specific half-life influencing dosing frequency. Understanding the pharmacokinetics is essential for determining appropriate dosing regimens and managing potential drug interactions.

Pregnancy

Consult healthcare provider for advice; safety not established.

Breast-feeding

Consult healthcare provider for advice; safety not established.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Pain management
• Inflammation
• Fever reduction

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing guidelines.

Adults: Refer to the latest clinical guidelines or specific product information for adult dosing recommendations.

Mechanism of action

Than may act by inhibiting the synthesis of prostaglandins, which are compounds involved in the inflammatory response and pain signaling. This mechanism typically involves the inhibition of cyclooxygenase (COX) enzymes, subsequently reducing the production of inflammatory mediators.

Pharmacodynamics

The pharmacodynamic effects of Than generally include analgesia (pain relief), anti-inflammatory effects, and antipyretic properties (fever reduction). Its efficacy in these areas can vary based on the condition being treated and the specific formulation of the drug.

Pharmacokinetics

Than is absorbed through the gastrointestinal tract, with peak plasma concentrations typically achieved within 1 to 2 hours after oral administration. It is metabolized primarily in the liver and excreted via the kidneys. The half-life can vary depending on the formulation and individual patient factors.

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare professional for advice.

Breast-feeding

Use with caution. Monitor infant for potential adverse effects. Consult a healthcare professional for advice.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Preservative in vaccines
• Antibacterial agent
• Antifungal agent

Dosage

Children: Refer to the BNF for Children for specific dosage guidelines, especially in

Adults: Refer to specific product guidelines or the BNF for detailed dosage information, as thimerosal is primarily used as a preservative in vaccines rather than in therapeutic doses.

Mechanism of action

Thimerosal inhibits sulfhydryl-containing active sites of various enzymes and binds to sulfhydryl compounds, including glutathione and cysteine. It activates the InsP3 calcium channel on the endoplasmic reticulum, leading to the release of intracellular calcium and subsequent cellular functions dependent on calcium signaling. Ethylmercury, the metabolite of thimerosal, is lipophilic and can cross the blood-brain barrier, contributing to its biological effects.

Pharmacodynamics

Thimerosal exhibits antibacterial and antifungal properties, functioning as a preservative in vaccines. Its pharmacological effects are mediated through interactions with cellular thiols and modulation of calcium signaling pathways. The toxic effects of high doses of thimerosal, such as oxidative stress and apoptosis, have been observed in vitro, although the effects of low-dose exposure remain less understood.

Pharmacokinetics

Thimerosal is rapidly metabolized to ethylmercury, which is eliminated from the body more quickly than methylmercury. Ethylmercury has a shorter half-life, leading to limited accumulation and toxic potential when used in vaccine formulations. The octanol/water partition coefficients indicate that both organomercury compounds, including ethylmercury, can primarily exist within cells, allowing them to cross cellular membranes effectively.

Adverse effects

• Hypersensitivity reactions
• Local reactions at injection site
• Neurotoxic effects at high doses
• Possible kidney pathology with toxic quantities

Precautions

• Use with caution in individuals with known hypersensitivity to thimerosal or other mercury compounds
• Monitoring for adverse effects in patients receiving multiple vaccines containing thimerosal

Pregnancy

Thimerosal should be used in pregnant women only if clearly needed, as the effects on fetal development are not fully established.

Breast-feeding

Thimerosal is considered compatible with breastfeeding, but caution is advised due to potential mercury exposure.

Storage

Store in a cool, dry place away from light. Protect from freezing. Ensure proper disposal of any unused or expired vaccine containing thimerosal.

Formulations

• Thimerosal-containing vaccines (various formulations)

Mechanism of action

180 to 200 times sweeter than sucrose, it is metabolized as a protein and its subsequent amino-acids used up in there respective mechanisms.

Pharmacodynamics

Aspartame (L-alpha-aspartyl-L-phenylalanine methyl ester) is a low-calorie sweetener used to sweeten a wide variety of low- and reduced-calorie foods and beverages, including low-calorie tabletop sweeteners. Aspartame is composed of two amino acids, aspartic acid and phenylalanine, as the methyl ester. Aspartic acid and phenylalanine are also found naturally in protein containing foods, including meats, grains and dairy products. Methyl esters are also found naturally in many foods such as fruits and vegetable and their juices. Upon digestion, aspartame breaks down into three components (aspartic acid, phenylalanine and methanol), which are then absorbed into the blood and used in normal body processes. Neither aspartame nor its components accumulates in the body. These components are used in the body in the same ways as when they are derived from common foods.

Mechanism of action

Although its mechanism of action is not fully understood, thimerosal inhibits sulfhydryl-containing active site of various enzymes and binds to sulfhydryl compounds, including glutathione, cysteine, and sulfhydryl groups of proteins. In addition, thimerosal activates the InsP3 calcium channel on the endoplasmic reticular membrane, thereby triggering the release of intracellular calcium resulting in a calcium-induced calcium-influx of extracellular calcium. Therefore, thimerosal may induce or inhibit various cellular functions that are dependent on the signaling of calcium. Ethylmercury is metabolized to inorganic mercury more rapidly than methylmercury. This difference in metabolism may account for kidney pathology that can result from toxic quantities. Also, whereas the increase in oxidative stress and induction of apoptosis observed in vitro with large doses (405 μg/L to 101 mg/L) of thimerosal may explain its damaging neurological effects. The effects of low-dose ethylmercury are not completely understood to date. It is known, however, that the shorter half-life of ethylmercury (the metabolite of thimerosal) allows for very limited opportunities of ethylmercury derived from thimerosal in vaccines. Ethylmercury is a lipophilic cation that is capable of crossing the blood-brain barrier. The octanol/water partition coefficients of methyl and ethylmercury are 1.4 to 1.8, at intracellular pH and [Cl−], therefore, both organomercury compounds will primarily exist as intracellular lipophilic cations. It has been demonstrated that lipophilic cations accumulate inside mitochondria, in a Nernstian fashion, driven by the steady state membrane potential. As the typical mitochondrial membrane potential of astrocytes and neurons is between 140–170 mV, one would expect the concentration of these organomercury compounds within mitochondria to be approximately 1000 times greater than the cytosolic concentration.

Pharmacodynamics

Thimerosal is an organomercurial compound and derivative of thiosalicyclic acid with antibacterial and antifungal properties. Thimerosal, which consists of approximately 50% mercury by weight, has been one of the most widely used preservatives in vaccines. It is metabolized/degraded to ethylmercury and thiosalicylate. Ethylmercury is an organomercurial that must be carefully distinguished from methylmercury, a closely related substance that has been the focus of many studies. Methylmercury is the type of mercury found in various species of fish. Experimental data demonstrates that the toxicokinetics of thimerosal (ethylmercury) is vastly different from that of methyl-mercury. Thus, methyl-mercury is not a suitable reference for assessing the risk from exposure to thimerosal-derived mercury. Prior to the recent initiative to reduce or eliminate thimerosal from childhood vaccines, the maximum cumulative exposure to mercury via routine childhood vaccinations during the first 6 months of life was 187.5 micrograms. In the most recently formulated vaccines, the maximum cumulative exposure during the first 6 months of life should now be less than 3 micrograms of mercury. Currently, thimerosal may still be used in the early stages of manufacturing of certain childhood vaccines, however, only a trace remains after a chemical purification process. Note that the dose above is indicated for children 1-6 months of age is applicable only in the United States, and other countries may have varying indications.